 Silverback Therapeutics Inc NASDAQ: SBTX recently raised 277.7 million by selling 13.225 million shares in an initial public offering that were priced at 21 each. The Silverback Analyst: SVB Leerink analyst Daina Graybosch initiated coverage of Silverback Therapeutics with an Outperform rating and 40 price target. 